Suggested remit: To appraise the clinical and cost effectiveness of isatuxmab in combination within its marketing authorisation for treating multiple myeloma when a stem cell transplant is unsuitable.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback